Cell therapy’s access bottleneck reaches deep into hospital operations
Manufacturers, delivery specialists and patient advocates described shared infrastructure needs while disagreeing about what payers still need to know.
Hospitals cannot scale cell and gene therapy by building a separate administrative program for every specialty, Basepath Health co-founder and CEO Akshara Reddy argued. She described a move toward enterprise capabilities for finding eligible patients, clearing prior authorization and coordinating treatment across departments as therapies expand beyond the oncology programs that first developed much of that expertise.
Reddy said onboarding a therapy and treating the first patient can take months and, in some cases, close to a year. Her account placed an access problem inside the delivery system: even when a treatment exists, the hospital still needs a coordinated clinical, operational and financial process before it can provide it.
The November 17 When the Cure Has a Cost discussion paired that view with Lynelle Hoch, president of the cell therapy organization at Bristol Myers Squibb, and Nasha Fitter, co-founder and CEO of the FOXG1 Research Foundation. Josh Flum, managing partner at LRVHealth, facilitated, describing a problem in which manufacturers, payers and providers need one another to move before access can expand.
Build a capability across specialties
Reddy described the limits of a bespoke model developed for CAR-T within oncology. As different therapies reach other specialties, replicating patient-identification systems, financial coordinators and administrative processes becomes expensive. A hospital-wide program can instead help clinical service lines decide which therapies to offer and how to prepare for them.
“We can't afford to hire financial coordinators for every single specialty,” Reddy said. She described enterprise guidance that brings clinical, operational and financial decisions together, including examining the electronic record for potentially eligible patients. That identification work, she said, remains highly manual in many organizations.
Her argument was about readiness rather than a claim that every hospital should administer every product. An organization still has to assess its population, capabilities and the demands of a particular therapy. Shared infrastructure is intended to make those decisions and the subsequent treatment journey more coordinated, rather than recreate the administrative machinery each time.
Community access requires a treatment model
Hoch identified education, site of care and referral relationships as major barriers. Patients and clinicians need to understand eligibility, she said, and treatment capacity must reach beyond a limited set of academic centers. Referring physicians also need to hear what happened to their patients and remain part of their continuing care.
“The mission isn't done by developing these drugs and commercializing these drugs,” Hoch said. She described access as a responsibility that continues after a product enters the market. A community physician who loses visibility after referral cannot easily help coordinate what comes next, even when the treatment itself succeeds.
Hoch also argued that the delivery model should be considered during development. She discussed incorporating home monitoring into a study protocol to support patient confidence and treatment-center readiness, and considering toxicity and outpatient delivery together. These were development and care-design considerations, not a declaration that all cell therapies are ready for routine administration in every community setting.
She described ongoing research into additional cell-therapy approaches and disease areas as reasons the access problem could grow. The panel’s concern was prospective as well as immediate: a system that struggles to serve today’s eligible population may face a much larger coordination challenge if future indications and technologies succeed.
Families are building part of the evidence base
Fitter approached the discussion as a caregiver, research-foundation leader and rare-disease technology entrepreneur. She described patient organizations assembling natural-history information because a poorly understood disease trajectory can make a development program harder to design and evaluate. Those groups may be creating the evidence needed to make a condition more feasible for researchers to pursue.
“We do not know how to develop drugs for small groups of people,” Fitter said. Her criticism targeted the economics and processes used for very small populations. A development model suited to a large market may become financially unworkable when additional manufacturing and trial phases must be supported by a few hundred potential patients.
She argued for better baseline data, more efficient development and technology that can support follow-up without requiring an expensive manual process for every observation. She described the foundation’s experimental gene-therapy work as part of that effort. The discussion did not announce an approval or establish that an investigational treatment is a cure.
“In order for the price tags to come down, we have to do drug development more efficiently,” Fitter said. She supported the value of treatment while challenging whether very high prices can be sustained across many rare diseases. That put development cost, not only reimbursement design, into the access debate.
Long-term information and near-term value
Reddy, who described prior experience at Aetna, said payers seek predictability about real-world outcomes. She argued for technology and services that can follow people across years, support timely intervention and produce information useful for outcomes-based agreements. Her proposal brought manufacturers, providers and payers into the same infrastructure discussion.
“Outcomes tracking capability is so fundamental here in order to unlock the payer side of the equation,” Reddy said. She was describing a capability gap from her delivery-system perspective, rather than presenting a finding that no useful evidence exists for any cell therapy. Different products and indications have different evidence histories.
The FDA’s long-term follow-up guidance is likewise risk-based: not all gene-therapy products require the same observations. Reddy’s discussion of a 15-year horizon should not be read as one uniform follow-up rule for every treatment. Safety surveillance, clinical effectiveness and the evidence needed for a payment agreement are related but distinct tasks.
Hoch directly challenged the implication that payers must wait for much more information before recognizing CAR-T’s value. She argued that established autologous therapies already have substantial experience behind them and that delaying labeled use can mean additional treatment costs and diminished opportunity for patients. “I really do encourage payers to challenge how they look at value,” she said.
That disagreement left the discussion with two responsibilities rather than a single answer. Delivery organizations need stronger coordination and continuing outcomes information; payers must also evaluate the evidence already available for an eligible patient today. Fitter’s challenge adds a third: expand access without assuming that the cost structure of developing treatments for small populations can remain unchanged.